SequelSEC

Kymera Therapeutics, Inc. KYMR

Biological Products, (No Diagnostic Substances) · CIK 0001815442 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$102.24M
Fiscal year ended 2026-09-30
Operating income
-$404.89M
Fiscal year ended 2026-09-30
Free cash flow
-$288.89M
Fiscal year ended 2026-09-30

Valuation, from the filing

Public float$2.29BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-12-31
Float per share$28.11Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue58.5×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-12-31, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin0.0%5th
Current ratio10.47x84th
SBC / revenue152.8%75th
Revenue YoY growth-16.7%33th
FCF margin-597.6%36th
R&D / revenue807.3%61th
Operating margin-891.1%39th
Net margin-794.0%40th
CapEx / revenue3.7%51th

Kymera Therapeutics, Inc. (KYMR) reported revenue of $102.24M and net income of -$349.42M for the fiscal year ended 2026-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Kymera Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Kymera Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Revenue$102.24M
Cost of revenue$102.24M
Gross profit$0
Operating income-$404.89M
Net income-$349.42M
Research & development$429.98M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$77.14M
Selling & marketingUnavailable

Balance

Kymera Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Cash & equivalents$373.37M
Total assets$1.77B
Current assets$998.59M
Total liabilities$152.74M
Current liabilities$89.72M
Total equity incl. NCI$1.61B
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$11.92M

Cash flow

Kymera Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Operating cash flow-$287.56M
Capital expenditures$1.33M
Investing cash flow-$415.56M
Financing cash flow$963.97M
Net change in cash$260.85M
Stock-based compensation$68.24M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$8.11M

Derived

Kymera Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Free cash flow-$288.89M
Gross margin0.0%
Operating margin-396.0%
FCF margin-282.6%
SBC / revenue66.7%
Current ratio11.13x
Revenue YoY growth133.8%
Net margin-341.8%
R&D / revenue420.6%
CapEx / revenue1.3%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open KYMR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-10-29View SEC filing
10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-11View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.